Lazarus Effect ReCover™ Thrombectomy Device Receives CE Mark

Informations

• Publié par: nfocus-neuromedical-inc
• Nombre de lectures: 39
• Langue: English

Extrait

Lazarus Effect ReCover™ Thrombectomy Device Receives CE Mark

PR Newswire CAMPBELL, California, July 24, 2012

- Next-generation device for ischemic stroke treatment integrates gold standard stent-based clot retriever with integrated protective cover - CAMPBELL, California,July 24, 2012/PRNewswire/ -- Lazarus Effect, a medical device company focused on improving treatment of acute ischemic stroke through effective removal of the blood clots that cause a stroke, announced today that the Lazarus ReCover™ Thrombectomy Device hasreceived CE Mark. The Lazarus ReCover is a next-generation ischemic stroke device that addresses a major limitation of stent-based clot retrieval, the current gold- standard technology for clot removal, by integrating a protective cover intended to prevent clot fragmentation or embolism and the potential for secondary stroke. Lazarus Effect plans to launch the Lazarus ReCover inEuropeduring Q1 2013. The company is currently evaluating distribution partners. Stent-based thrombectomy (clot removal) devices have demonstrated success "capturing" clots within the affected vessel, but often lose thrombus as the device is extracted. Among 124 Solitaire™ stent retriever cases evaluated during a recent European study, lost clot pieces traveled into an area of the brain previously not affected nine percent of the time, causing new areas of brain to experience stroke. The ReCover device comprises a nitinol wire-wrapped stent with a highly visible, radio-opaque core and a nitinol mesh cover that surrounds the stent and thrombus during retrieval to help prevent clot fragmentation and embolization. The device will be presented for the first time at the Society for Neurointerventional Surgery (SNIS) Annual Meeting,July 23-27inSan Diego, CA. "The Lazarus ReCover is a significant advancement in the stent-based retriever category," said Martin Dieck, chairman and CEO, Lazarus Effect. "By integrating protection directly onto the proven stent retriever design, Lazarus Effect has reduced the number of devices that may be needed for the procedure, decreasing complexity and saving critical time while simultaneously creating a device that should be more effective at preventing thrombus loss during removal." Approximately two million strokes occur inEuropeeach year. Seventy-eight percent of these are ischemic and caused by a dislodged blood clot or arterial plaque debris traveling to the brain and blocking a cerebral artery. "In the past few years we have seen a dramatic increase in the number of ischemic strokes treated inEurope. This is partly due to treatment centers experiencing improved recanalization rates with stent retrievers," said J Mocco, MD, MS, FAHA, FAANS, a leading stroke interventionalist and the principal investigator of THERAPY, an international randomized stroke trial. "However, there are still serious concerns over the loss of thrombus during clot retrieval. The ReCover device offers innovative, easy-to-use technology designed to address these concerns and therebim roveatient outcomes."

Patients who are ineligible for intravenous tissue plasminogen activator (IV t- PA) or who fail IV t-PA therapy are candidates for treatment with the ReCover. About Lazarus Effect Lazarus Effect is generating a complete portfolio of products to treat ischemic stroke based on a patent-pending wire-frame technology platform. The company's founders are proven pioneers of ischemic stroke treatment with significant involvement in every aspect of the ischemic stroke business, technology and treatment. More information can be found at www.lazarus- effect.com.